Neurocrine Biosciences Stock Price and Value Analysis

Should you buy Neurocrine Biosciences stock? (NasdaqGS:NBIX). Let's see how it does in our automated value investing analysis system.

  • This company is solid.
  • This company is not making money.
  • This stock looks overpriced.
  • This company has wild ups and downs.
  • This company pays no dividend.

Inside the NBIX Numbers

NBIX Price
(Neurocrine Biosciences stock price per share)
[?] PE Ratio versus Sector 38% higher than other Healthcare stocks
[?] PE Ratio versus Industry 51% lower than other Biotechnology stocks
[?] Cash Yield -0.33%
[?] Free Cash Flow Jitter 1307%

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 2,737,944 shares shorted. With 94,356,798 shares available for purchase and an average trading volume over the past 10 trading days of 664,340, it would take at least 4.121 days for all of the short holders to cover their shorts.

Is Neurocrine Biosciences Stock on Sale?

Based on our analysis, we believe that you should not buy Neurocrine Biosciences right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy NBIX Stock?

Does Neurocrine Biosciences have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.